DARZALEX ® SC combination regimen is supported by the Phase 3 ANDROMEDA study demonstrating a significantly higher hematologic complete response rate in this rare and serious blood cell disorder ...
Findings showed treatment with D-VCd significantly improved MOD-PFS and OS vs treatment with VCd. The Food and Drug Administration (FDA) has granted traditional approval to Darzalex Faspro ® ...
SAN DIEGO — Final results of the phase 3 Andromeda study confirmed that adding daratumumab (DARA) — a human CD38-targeting monoclonal antibody — to bortezomib, cyclophosphamide, and dexamethasone (VCd ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results